Jonathan Poh
About Jonathan Poh
Jonathan Poh is the Chief Technology Officer and a co-author of multiple publications on cancer detection and liquid biopsy technologies.
Chief Technology Officer
Jonathan Poh serves as the Chief Technology Officer. In this role, he brings extensive expertise in technology and research, particularly focused on cancer detection and liquid biopsy technologies. His leadership is instrumental in advancing the development and implementation of cutting-edge diagnostic tools, enabling more accurate and early detection of various cancers.
Publications on Cancer Detection
Jonathan Poh has co-authored multiple publications on cancer detection and liquid biopsy technologies. His research has been featured in renowned scientific journals such as Annals of Oncology, Journal of Clinical Oncology, and the American Association for Cancer Research. These publications highlight Poh's contributions to the field and his dedication to advancing cancer diagnostics.
Expertise in cfRNA Sequencing for Lung Cancer
Jonathan Poh possesses specialized expertise in plasma cell-free RNA (cfRNA) sequencing for lung cancer detection. His work in this area focuses on the utilization of cfRNA as a biomarker to identify lung cancer at early stages, improving the overall accuracy and outcomes of lung cancer diagnostics.
Multi-Cancer Screening Tests
Jonathan Poh is involved in developing and evaluating multi-cancer screening tests for cancers common in Asia. His efforts aim to enhance early detection rates and diagnostic accuracy for a range of cancers prevalent in the region. This work is crucial for improving patient outcomes and reducing the burden of cancer through early intervention.
Research on Mutation Concordance
Jonathan Poh has participated in research examining mutation concordance between peripheral blood and bone marrow using amplicon-based next-generation sequencing (NGS). This research contributes to a better understanding of genetic mutations in cancer, supporting the development of more precise and effective diagnostic and treatment strategies.
Liquid Biopsy and PET/CT for Lung Cancer Diagnosis
Jonathan Poh has contributed to studies exploring the combination of liquid biopsy with PET/CT for the diagnosis of lung cancer. This research aims to enhance diagnostic accuracy by integrating multiple advanced technologies, providing comprehensive insights into the presence and progression of lung cancer.